Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commercial potential, with analysts projecting modest long-term sales. Revuforj offers significant upside, targeting an underserved leukemia niche with minimal competition and potential for label expansion pending FDA review.
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Director Steve Closter - Chief Commercial Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Jason Zemansky - Bank of America Ellen Horste - TD Cowen Peter Lawson - Barclays Michael Schmidt - Guggenheim David Dai - UBS Yigal Nochomovitz - Citi Kalpit Patel - B. Riley Securities Jeet Mukherjee - BTIG Salim Syed - Mizuho George Farmer - Scotiabank Operator Good day, everyone, and welcome to the Syndax First Quarter 2025 Earnings Conference Call.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago.
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gallagher - President and Head of R&D Keith Goldan - CFO Anjali Ganguli - CSO Conference Call Participants Anupam Rama - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - Jefferies Michael Schmidt - Guggenheim Yigal Nochomovitz - Citi David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Jason Zemansky - Bank of America Operator Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $1 per share a year ago.
US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% in after-hours trading.
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President & Head, R&D Steve Closter - Chief Commercial Officer Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Priyanka Grover - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - Jefferies Phil Nadeau - TD Cowen Michael Schmidt - Guggenheim Ashiq Mubarack - Citi Jason Zemansky - Bank of America George Farmer - Scotiabank Kalpit Patel - B. Riley Securities Justin Zelin - BTIG Operator Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call.
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago.
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript
FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
Shares of Syndax Pharmaceuticals (SNDX) plunged in intraday trading Monday after the biopharmaceutical company reported that the Food and Drug Administration (FDA) delayed a decision on approving its experimental treatment for acute leukemia.
